The combination of a strong Q1 beat, raised full-year guidance, and FDA approval for the aura6000 OSA system creates a powerful catalyst. The OSA market entry with a differentiated device (no contraindication for complete concentric collapse) could drive significant long-term growth. Monitor the upcoming conference call for initial commercialization plans and reimbursement strategy for aura6000.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 6 $66.26entry
- T+1 · 6mo ago +7.04%α +7.37% · $70.93
- T+5 · 6mo ago +8.29%α +7.15% · $71.75
- T+20 · 6mo ago +7.65%α +4.87% · $71.33
- T+60 · 4mo ago +20.95%α +18.89% · $80.14
Price Chart
How similar events traded
Executive Summary
LivaNova reported Q1 2026 revenue of $362.3M (+14.3% YoY reported, +11.1% constant-currency), beating consensus of $346.1M. Adjusted diluted EPS of $0.98 exceeded the consensus estimate of $0.90 by 8.9%. The company raised full-year 2026 guidance: revenue growth raised 100bps to 7-8% constant-currency and adjusted EPS raised $0.05 to $4.20-$4.30. Additionally, the FDA granted premarket approval for the aura6000 System for obstructive sleep apnea, a significant new product catalyst.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $362.3M, +14.3% reported / +11.1% constant-currency YoY, above $346.1M consensus
- Q1 2026 adjusted diluted EPS $0.98, vs $0.90 consensus (beat by 8.9%)
- Raised FY2026 revenue growth guidance to 7.0%-8.0% constant-currency (from 6.0%-7.0%)
- Raised FY2026 adjusted EPS guidance to $4.20-$4.30 (from $4.15-$4.25)
- FDA premarket approval received for aura6000 System for moderate-to-severe obstructive sleep apnea
- Cardiopulmonary revenue +18.3% reported (+14.0% constant-currency); Neuromodulation +9.3% reported (+7.6% constant-currency)
- Adjusted operating income $71.1M, up from $64.6M in Q1 2025
- Adjusted free cash flow $3.8M in Q1 2026
Financial Impact
Revenue beat of ~$16.2M vs consensus; EPS beat of $0.08 vs consensus; guidance raised for both revenue and EPS
Risk Factors
- OSA market entry is still early-stage; commercialization and reimbursement timelines uncertain
- GAAP operating income declined to $41.5M from $48.6M due to higher R&D spending ($58.7M vs $37.9M) for OSA investments
- Adjusted free cash flow was only $3.8M, down from prior periods, though this is seasonally low
- 3T Heater-Cooler litigation and SNIA environmental liabilities remain overhangs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001639691-26-000031 |
| Document: livn-20260506.htm | 0001639691-26-000031 |
| Document: 0001639691-26-000031-index-headers.html | 0001639691-26-000031 |
| Document: 0001639691-26-000031-index.html | 0001639691-26-000031 |
| Document: 0001639691-26-000031.txt | 0001639691-26-000031 |
| 8-K Data (Synthetic) | 0001639691-26-000031 |
Track record
10 reports on LIVN
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $91.32 Now $92.44 +1.23% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $90.98 Now $92.44 +1.60% settles Feb 9
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $91.14 Now $92.44 +1.43% settles Feb 3
- Nov 4, 202612d ago 8-K Bullish 6/10 Entry $94.19 Now $92.44 −1.86% settles Feb 2
- Sep 14, 20269w ago Insider Cluster Neutral 2/10 Entry $79.47 Now $92.44 +16.32% settles Dec 9
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $78.93 Now $92.44 +17.12% settles Dec 3
- Aug 5, 202614w ago 8-K Bullish 7/10 Entry $78.15 to $81.52 Now $92.44 +18.29% ▲ +4.32% +4.13% vs SPY
- May 6, 202627w ago 8-K Bullish 8/10 Viewing Entry $66.26 to $80.14 Now $92.44 +39.51% ▲ +20.95% +18.89% vs SPY
- Apr 29, 202628w ago DEFA14A Neutral 2/10 Entry $58.92 to $78.19 Now $92.44 +56.89% ▲ +32.71% +28.59% vs SPY
- Feb 25, 202637w ago 8-K Bullish 7/10 Entry $70.29 to $73.71 Now $92.44 +31.51% ▲ +4.87% −2.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers